The utility of hyperthermia for local recurrence of breast cancer

Daigo Yamamoto1,3*, Toshio Inui2, Yu Tsubota1, Noriko Sueoka1, Chizuko Yamamoto3, Kayoko Kuwana1 and Mitsuo Yamamoto3

Abstract

Background: Hyperthermia has long been used in combination with chemotherapy or radiation therapy for the treatment of superficial malignancies, in part due to its sensitizing capabilities. Patients who suffer from superficial recurrences of breast cancer have poor clinical outcomes. Skin metastases may particularly impair the quality of life due to the physical appearance, odor and bleeding.

Case presentation: A 66-year-old woman underwent mastectomy and axillary lymph node dissection for breast cancer. Nine years post-operatively, local metastases developed in the left axillary area (measuring 5 cm in diameter). Initially the tumor did not respond to radiation therapy and chemotherapy. Therefore, we added hyperthermia combined with them. Eight weeks later, the tumor became nearly flat and the patient noted improved activity in her daily life.

Conclusion: Hyperthermia may accelerate the antitumor effects of radiation therapy and chemotherapy. This treatment provides an alternative for unresectable breast cancer skin metastases.

Keywords: Breast cancer, Skin metastasis, Hyperthermia

Background

Hyperthermia has been combined with radiotherapy in an effort to improve local control, which is essential in unresectable locally advanced breast cancer (LABC). Hyperthermia’s ability to affect cells in S phase, inhibit sub-lethal damage repair, and improve oxygenation make it an attractive therapy to combine with radiation and/or chemotherapy in the hopes of synergy [1-5]. The ultimate goal of the addition of hyperthermia to treatment for LABC is improved tumor kill, which most often is assessed with the rate of clinical complete response/partial response (cCR/pPR), and if the patient undergoes surgery, pCR. In addition to the inherent biology of an individual tumor, achieving a CR with thermoradiotherapy depends on the size of the tumor, dose of radiotherapy used, and ability to adequately heat the tumor, which can be especially challenging with large burdens of unresectable disease [6].

Case presentation

A 66-year-old woman underwent mastectomy and axillary lymph node dissection for breast cancer. The histopathological findings were papillo-tubular carcinoma with metastases in two axillary lymph nodes. IHC staining showed that estrogen receptor (ER) and progesterone receptor (PR) were positive, and Human Epidermal Growth Factor Receptor 2 (HER-2) oncoprotein was negative. As adjuvant therapy, doxorubicin (60 mg/m²) and cyclophosphamide (600 mg/m²) were administered four times and aromatase inhibitor was prescribed for five years. There was no post-mastectomy radiotherapy (PMRT). Nine years post-operatively, local metastases developed in the left axillary area. Chemotherapy (weekly paclitaxel: 80 mg/m²) and radiotherapy (total 30 Gy) were attempted, but the lesions continued to enlarge. On examination, a tumor measuring 5 cm in diameter was found in the left axillary area (Figure 1A). Therefore, we added hyperthermia combined with radiotherapy and chemotherapy. Hyperthermia was performed using a Thermotron RF-8 capacitive heating device (Yamamoto VINITA Co., Ltd., Osaka, Japan) at a surface temperature of 38°C to 41°C, once a week for 50 minutes [6]. The output power ranged...
from 1,300 to 1,400 W. After four weeks, the surface of the tumor began to dissolve, then became gradually necrotic (Figure 1B). Along with a reduction of the tumor size, the foul odor disappeared. Eight weeks later, the tumor became nearly flat and the response was evaluated as a complete response (CR), according to the Response Evaluation Criteria in Solid Tumors Group criteria, and the patient noted improved activity in her daily life (Figure 1C).

Discussion

Breast cancer is the most common neoplasm to metastasize to the skin. Skin metastases impair activities of daily life due to the physical appearance, odor and bleeding. In the present study, chemotherapy (weekly paclitaxel: 80 mg/m2) and radiotherapy (total 30 Gy) were attempted, but the lesions continued to enlarge. On examination, a tumor measuring 5 cm in diameter was found in the left axillary area (Figure 1A). Therefore, we added hyperthermia combined with the other therapies. In general, the first-line therapy for lymphadenopathy is radiotherapy in which the area was irradiated (total 30 Gy). Thus, we selected hyperthermia, as the radiotherapy (total 30 Gy) was already applied to the area of axillary lymphadenopathy. As a result, we succeeded in controlling these symptoms through the combined application of chemo-radiation therapy and hyperthermia, which resulted in a greatly improved quality of life.

Hyperthermia has been investigated in several randomized and non-randomized clinical trials for cancer therapy [7-11]. Hyperthermia can increase the therapeutic ratio by enhancing the permeability of tumor blood vessels to liposomes. In pre-clinical studies it has been demonstrated that the rate of liposomal extravasation is enhanced four- to eight-fold for temperatures in the target range of this trial [12]. In cats with soft tissue sarcomas, hyperthermia enhanced radio-labeled liposomal uptake by 4- to 16-fold compared to normothermia [13]. Hyperthermia also increases oxygen levels within the tumor, which is critical to the effectiveness of radiation and chemotherapy [14-17]. In a clinical setting, some recent studies [18,19] showed that neoadjuvant chemotherapy combined with hyperthermia is a feasible and well-tolerated treatment strategy in breast cancer patients. In this study [18], 19 of 44 patients were deemed inoperable at the initial assessment. Fourteen of these patients had inflammatory disease. Only five patients were candidates for breast-conserving surgery (BCS). Eight patients elected to have BCS, although 16 were eligible after reassessment following neoadjuvant treatment. At surgery, 32 patients (73%) were found to have axillary lymph node involvement. No patients progressed during neoadjuvant therapy. A complete pathological response was seen in four patients (9%). The combined pathological response was 60% (CR: 9%, and PR: 51%). Therefore, there is a possibility that the addition of HT to preoperative chemotherapy increases cCR and pCR rates more so than chemotherapy alone. In our previous studies, patients with pCR to chemotherapy had a favorable prognosis [20,21]. Thus, the goal of adding hyperthermia to radiotherapy and/or

Figure 1 Skin metastasis from breast cancer was found in the left axillary area. (A) Before hyperthermia. The diameter of the tumor was 5 cm. Four weeks (B) and eight weeks (C) later, the tumor showed gradual shrinkage.
chemotherapy is to increase response rates, and hopefully local control and disease-free survival.

Conclusions
In conclusion, multidisciplinary therapy, such as hyperthermia, radiotherapy and chemotherapy, may be a useful and effective method for the treatment of progressive breast cancer.

Consent
Written consent was obtained from the patient for publication of this study and the related photos.

Abbreviations
BCS: Breast-conserving surgery; cCR: Clinical complete response; CR: Complete response.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
DY, YT, NS, and KK performed chemotherapy as a team. TI and CY treated the patient using hyperthermia. DY drafted the manuscript. MY carried the data acquisition. All authors read and approved the final manuscript.

Acknowledgements
We would like to thank staff in Inui Clinic for assisting in the preparation of this manuscript.

Author details
1Department of Surgery, Kansai Medical University, Hirakata, Japan. 2Iuni Clinic, Moriguchi, Japan. *Department of Internal Medicine, Seiko Hospital, Neyagawara, Osaka, Japan.

Received: 10 July 2012 Accepted: 21 September 2012 Published: 27 September 2012

References
1. Westra A, Dewey WC. Variation in sensitivity to heat shock during the cell-cycle of Chinese hamster cells in vitro. Int J Radiat Biol Relat Phys Chem Med 1971, 19:467–477.
2. Kampinga HH, Dikomey E. Heat shock proteins: a comparative study of heat shock proteins in human cells. Heat Shock Prot 2006, 32:331–339.
3. Raaphorst GP, Ng CE, Yang DP. Hyperthermia: an overview. Int J Radiat Oncol Biol Phys 1996, 35:407–411.
4. Dewhirst MW. Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol 1998, 8:143–150.
5. Zagar TM, Oleson JR, Vujaskovic Z, Dewhirst MW, Craciunescu OI, Blackwell KL, Prosnitz LR, Jones EL. Hyperthermia for locally advanced breast cancer. Int J Hyperthermia 2010, 26:618–624.
6. Uto Y, Horii H, Kubo K, Ichihashi M, Sakamoto N, Mette M, Inui T. GcMAF: our next generation immunotherapy. Nature 2012, 485:567–570.
7. Jones EL, Oleson JR, Prosnitz LR, Samuelski TV, Vujaskovic Z, Yu D, Sanders LL, Dewhirst MW. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005, 23:3079–3085.
8. Vernon CC, Hand JW, Field SB, Machin D, Whaley JB, van der Zee J, van Putten WLJ, van Rhoon GC, van Dijk J, Gonzalez Gonzalez D. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials. Int J Radiat Oncol Biol Phys 1996, 35:731–744.
9. Lee HK, Antill AG, Perez CA, Stauber WL, Ramachandran G, Myerson RJ, Earnam M, Molmenti EP, Buckner A, Lockett MA. Superficial hyperthermia and irradiation for recurrent breast carcinoma of the chest wall: Prognostic factors in 196 tumors. Int J Radiat Oncol Biol Phys 1998, 40:365–375.
10. Hehr T, Lamprecht U, Glöckler S, Classen J, Paulsen F, Budach W, Bamberg M. Thermadiotherapy for locally recurrent breast cancer with skin involvement. Int J Hyperthermia 2001, 17:291–301.
11. Barnes JA, Dix DJ, Collins BW, Luft C, Allen JW: Expression of inducible Hsp70 enhances the proliferation of MCF-7 breast cancer cells and protects against the cytotoxic effects of hyperthermia. Cell Stress Chaperones 2001, 6:316–325.
12. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery. Effect of particle size. Cancer Res 2000, 60:4440–4445.
13. Matteucci ML, Anyarambahata G, Roosen G, Auma C, Fischer PE, Dewhirst MW, Needham D, Thrall DE. Hyperthermia increases accumulation of technetium-99 m-labeled liposomes in feline sarcomas. Clin Cancer Res 2000, 6:3748–3755.
14. Griffin RM, Oajirima K, Barrios B, Song CW. Mild temperature hyperthermia combined with carbogen increases tumor partial pressure of oxygen (pO2) and radio-sensitivity. Cancer Res 1996, 56:5590–5593.
15. Song CW, Shikl A, Osborn J, Iwata K. Tumour oxygenation is increased by hyperthermia at mild temperatures. Int J Hyperthermia 1996, 12:367–373.
16. Vujaskovic Z, Poroloz JM, Gaskin AA, Thrall DE, Page RL, Charles HC, MacFall JR, Bixler DM, Meyer RE, Prescott DX. Temperature-dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia treatment. Int J Radiat Oncol Biol Phys 2000, 46:179–185.
17. Thrall DE, Larue SM, Pratt AF, Case B, Dewhirst MW. Changes in tumour oxygenation during fractionated hyperthermia and radiation therapy in spontaneous canine sarcomas. Int J Hyperthermia 2006, 22:365–373.
18. Vujaskovic Z, Kim DW, Jones E, Lan L, McColl L, Dewhirst MW, Craciunescu OI, Staffler P, Loitcheva V, Betof A, Blackwelley K. A phase II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia 2010, 26:514–521.
19. Craciunescu OI, Thrall DE, Vujaskovic Z, Dewhirst MW. Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer. Int J Hyperthermia 2010, 26:625–637.
20. Iwasa S, Yamamoto D, Kurado Y, Kawaguchi T, Kitamura K, Odagiri H, Teramoto S, Akazawa K, Nagumo Y. Phase II trial of preoperative chemotherapy for breast cancer: Japan Breast Cancer Research Network (JBCRN)-02 trial. Anticancer Res 2011, 31:483–487.
21. Yamamoto D, Iwasa S, Yoshida H, Kurado Y, Yamamoto C, Kitamura K, Odagiri H, Nagumo Y. Efficacy of meloxicam in combination with preoperative chemotherapy for breast cancer - Japan Breast Cancer Research Network (JBCRN)-02 trial. Anticancer Res 2011, 31:5367–5371.

Cite this article as: Yamamoto et al.: The utility of hyperthermia for local recurrence of breast cancer. World Journal of Surgical Oncology 2012 10:201.

doi:10.1186/1477-7819-10-201

Submit your next manuscript to BioMed Central and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit